The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a more substantial loss in body weight and benefit metabolic health, particula